Cabometyx (cabozantinib) is indicated for the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
Cabometyx is available as film-coated tablets containing 20mg, 40mg or 60mg cabozantinib, allowing dosing at the recommended dose of 60mg once daily and also at the reduced doses recommended in case of suspected adverse drug reactions.
Cabozantinib, an inhibitor of multiple tyrosine kinases implicated in tumour growth and progression, is also available as Cometriq for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.
Prescribers should note that Cabometyx tablets and Cometriq capsules are not bioequivalent and should not be used interchangeably. If a patient must switch from cabozantinib capsules to tablets, they should continue at a Cabometyx dose not to exceed 60mg or the current Cometriq dose, whichever is lower.